Figure 7.

1-MT reverses the development of endometriosis in vivo. (a) Represent of ectopic lesions from PBS- (Ctrl), 1-MT-, ERi-, Vector-, or MRC2 sh-RNA-administered group. (b and c) Numbers of total ectopic lesions in mice administered PBS (n=8), 1-MT (n=9), estrogen receptor inhibitor (n=10), vector (n=8), and MRC2-shRNA (n=11). Values indicate mean±S.D., *P<0.05, **P<0.01, two-tailed, unpaired t-test. (d, e) Weights of total ectopic lesions from PBS (n=8), 1-MT (n=9), estrogen receptor inhibitor (n=10), vector (n=8) and MRC2-shRNA (n=11) administered groups in vivo. Values indicate mean±S.D., *P<0.05, two-tailed, unpaired t-test. (f and g) Flow cytometric analysis was used to determine Ki-67 expression (MFI) in ectopic lesions shown in PBS (n=8), 1-MT (n=9), estrogen receptor inhibitor (n=10) administration group in vivo. Values indicate mean±S.D., ***P<0.001, ****P<0.0001, two-tailed, unpaired t-test. ER_i, estrogen receptor inhibitor; si-MRC2, silenced-MRC2; Ctrl group, PBS administration group